Nano-X Imaging Receives FDA Clearance for TAP2D Image Enhancement, Advancing Regulatory Strategy
NNOX is trading near its 52-week low of $2.64 (12% above the low).
Summary
Nano-X Imaging Ltd. announced FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for its Nanox.ARC systems, marking a key step in its strategy to position these systems as primary diagnostic solutions.
Key Events · Product Development and Regulatory · NNOX
-
FDA 510(k) Clearance Received
Nano-X Imaging Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TAP2D.
-
New Image Enhancement Capability
TAP2D is a cloud-enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems.
-
Strategic Regulatory Advancement
This clearance is an important step in the company's regulatory strategy to position its tomosynthesis systems as primary diagnostic solutions, aiming to remove the 'adjunctive use' requirement in the U.S.
-
Improved Diagnostic Views
The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis scan, enabling both 3D and 2D views from a single scan without additional radiation exposure.
Analysis · NNOX · Industrial Applications And Services
This FDA 510(k) clearance for TAP2D is an important regulatory milestone for Nano-X Imaging, enhancing the capabilities of its Nanox.ARC and Nanox.ARC X systems. The new feature provides radiologists with both 3D and 2D views from a single tomosynthesis scan, improving diagnostic utility without additional radiation. Crucially, this clearance is a strategic step towards the company's goal of removing the 'adjunctive use' limitation in the U.S., which would allow its systems to function as standalone primary imaging solutions, significantly expanding their market potential and competitive positioning.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NNOX was trading at $2.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $173.4M. The 52-week trading range was $2.64 to $8.04. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.